Swedish diabetes company raises USD 17.5m for phase III trial
Diamyd Medical has raised funding through directed share issues to help construct production facilities and begin phase III study of its diabetes vaccine.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Among other things, the need for extra funding for a phase III study with Diamyd Medical's diabetes vaccine candidate has made the Swedish company carry out a directed share issue.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
